Gagan Kukreja’s Post

View profile for Gagan Kukreja, graphic

Associate Director, Medicinal Chemistry, SynVent IDD, Syngene

Kymera Therapeutics presents new clinical data from the ongoing Phase 1 trial of potent, highly selective STAT3 Degrader KT-333, a historically undrugged transcription factor at EHA Annual Meeting KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect achieved in blood and tumor Well-tolerated with Phase 1 dose escalation ongoing and additional data expected in the second half of 2024 https://lnkd.in/gxFube6Z

  • graphical user interface

To view or add a comment, sign in

Explore topics